Moberg Pharma AB (publ)
STO:MOB
Moberg Pharma AB (publ)
Operating Income
Moberg Pharma AB (publ)
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Operating Income
-kr324.8m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Operating Income
-kr353.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Operating Income
kr477.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Operating Income
-kr52.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Operating Income
kr225m
|
CAGR 3-Years
52%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Operating Income
-kr106.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
What is Moberg Pharma AB (publ)'s Operating Income?
Operating Income
-324.8m
SEK
Based on the financial report for Dec 31, 2024, Moberg Pharma AB (publ)'s Operating Income amounts to -324.8m SEK.
What is Moberg Pharma AB (publ)'s Operating Income growth rate?
Operating Income CAGR 3Y
-154%
Over the last year, the Operating Income growth was -1 083%. The average annual Operating Income growth rates for Moberg Pharma AB (publ) have been -154% over the past three years .
You don't have any saved screeners yet